Hesperos establishes strategic sales partnership with AsedaSciences

17 December 2025

Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds.

Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer limited throughput.

AsedaSciences’ combines high content phenotypic screens, machine learning (ML) and cloud computing to predict human and environmental safety risk, without the use of animals. Its SYSTEMETRIC cell health screen simultaneously measures in vitro 12 different phenotypic predictors of acute cellular stress. The multiparametric data generated during screening of each new compound is transformed using Aseda's proprietary ML algorithm. For reliable prediction of compound safety, the ML algorithm is trained on carefully curated training sets containing data on withdrawn, discontinued, and on-market drugs with known human safety profiles. To estimate drug permeability, protein binding, lipophilicity, and in vivo distribution, Aseda offers biomimetic chromatography screening services. For better interpretability, the biomimetic chromatography readouts are mapped onto real in vivo/clinical ADME outcomes using ML. Aseda's services also include intuitive data analytics visualization through its SaaS 3RnD® platform and actionable analysis of compound structure-activity relationships.

Hesperos is a pioneer and an industry leader in Human-on-a-Chip microfluidic systems for disease modelling, drug discovery, and efficacy-toxicity testing. Its human-based single‑organ and multi‑organ microphysiological systems generate compound safety, toxicity, mechanistic and efficacy readouts that empower its pharmaceutical, biotech and chemical industry clients to accelerate and de-risk compound development. Human-on-a-Chip-derived regulatory-grade datasets are frequently used in IND submissions. Hesperos’ human-relevant experimental biological outputs can be directly integrated into Aseda’s cloud‑based platform and compared to data from thousands of previously evaluated compounds, providing rich biological and contextual insights.

By deselecting early in the R&D process, anticipating the effects of compound design modifications and prioritising safer compounds, Aseda's and Hesperos' clients can gain a competitive edge, reduce product development costs, and accelerate time-to-market.

"Clients can seamlessly move from discovery to Hesperos’ IND-enabling human-based organ system models, combining early screening data with advanced preclinical insights for better informed, more predictive safety, efficacy, and PK/PD results", said Brad Calvin, CEO of AsedaSciences.